VR Logo

KalVista Pharmaceuticals Inc. (KALV) download report


Healthcare | Biotechnology & Pharma Research

KalVista Pharmaceuticals Inc. (KALV) Premium Coverage

53 Stocks to buy right now

Join Value Research Stock Advisor now and be among the first to discover Stock Ideas

ajax-loader
Please wait...

ajax-loader
Please wait...

ajax-loader
Please wait...

ajax-loader
Please wait...

ajax-loader
Please wait...

About The Company

Business: KalVista Pharmaceuticals, Inc., a clinical stage pharmaceutical company, discovers, develops, and commercializes small molecule protease inhibitors for diseases with unmet needs.

IPO Date: 09-Apr-2015

CEO & Director: Mr. Thomas Andrew Crockett M.B.A.

Chief Bus. Officer & CFO: Mr. Benjamin L. Palleiko

Listing: NASDAQ: KALV

Country: United States

Headquarters: Cambridge, MA

Website: https://www.kalvista.com

Key Facts

Market cap: $235.86 Mln

Revenue (TTM): $0.00 Mln

Earnings (TTM): $-72.03 Mln

Cash: $194.79 Mln

Total Debt: $0.00 Mln

Insider's Holding: 2.82%

Liquidity: Low

52 Week range: $8.00 - 24.80

Shares outstanding: 24,543,300

9 Years Aggregate:

  • CFO: $-200.53 Mln
  • EBITDA: $-184.71 Mln
  • Net Profit: $-221.33 Mln

Stock Performance

Time Period KalVista Pharmaceuticals (KALV) S&P BSE Sensex S&P Small-Cap 600
YTD-25.47-9.18-18.78
1 month9.80-4.78-8.00
3 months-33.11-9.66-13.65
1 Year-58.850.81-17.19
3 Years-23.6510.336.10
5 Years6.0211.345.87
10 Years--11.749.84
As on 01-Jul-2022
Year KalVista Pharmaceuticals (KALV) S&P Small-Cap 600 S&P BSE Sensex
2021-30.3325.2721.99
20206.639.5715.75
2019-9.8220.8614.38
2018101.79-9.705.87
201737.9111.7327.91
2016-86.0524.741.95